Skip to main content
SpringerLink
Log in

Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Despite the evidence indicating that long-acting injectable antipsychotics (LAIAs) are effective and safe options for the treatment of schizophrenia, various factors related to patients, clinicians and/or health policy makers have impeded their use. Solutions to overcoming these barriers include better communication of LAIA options, improved convenience and cost assistance, and guideline updates. Together, these strategies may result in more widespread prescribing of LAIAs for the treatment of schizophrenia, thereby facilitating improved patient outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701.

    Article  CAS  PubMed  Google Scholar 

  2. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–65.

    Article  PubMed  Google Scholar 

  3. Lafeuille M-H, Dean J, Carter V, et al. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin. 2014;30(8):1643–55.

    Article  CAS  PubMed  Google Scholar 

  4. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat. 2012;2012:407171.

    Google Scholar 

  5. Correll CU. Addressing barriers to using long-acting injectable antipsychotics and appropriately monitoring antipsychotic adverse effects. J Clin Psychiatry. 2013;74(8):e16.

    Article  Google Scholar 

  6. Bai YM, Chen TT, Chen J-Y, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68(8):1218–25.

    Article  CAS  PubMed  Google Scholar 

  7. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111–7.

    Article  CAS  PubMed  Google Scholar 

  8. Subotnik KL, Casaus LR, Ventura J, et al. Long-acting risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Buckley PF, Schooler NR, Goff DC, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2014;41(2):449–59.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181–9.

    Article  PubMed  Google Scholar 

  11. McDonnell DP, Andersen SW, Detke HC, et al. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights Psychiatry. 2011;3(2738):37–47.

    Article  Google Scholar 

  12. Lauriello J, Lambert T, Anderen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790–9.

    Article  CAS  PubMed  Google Scholar 

  13. McDonnell DP, Landry J, Detke HC. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study. Int Clin Psychopharmacol. 2014;29(6):322–31.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bushe CJ, Falk D, Anand E, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry. 2015;15:65.

    Article  PubMed  PubMed Central  Google Scholar 

  15. González-Rodríguez A, Catalán R, Penadés R, et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptibility: a review. Patient Prefer Adherence. 2015;9:695–706.

    PubMed  PubMed Central  Google Scholar 

  16. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–61.

    Article  PubMed  Google Scholar 

  17. Schreiner A, Bergmans P, Cherubin P, et al. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther. 2014;36(10):1372–88.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang F, Si T, Chiou C-F, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2015;11:657–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–9.

    Article  PubMed  Google Scholar 

  20. Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7) (pii: pyw018).

  21. Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330–9.

    Article  CAS  PubMed  Google Scholar 

  22. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135–44.

    Article  PubMed  Google Scholar 

  23. Ishigooka J, Nakamura J, Fujii Y, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicentre, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161(2–3):421–8.

    Article  PubMed  Google Scholar 

  24. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Carpenter WTJ, Buchanan RW. Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia. JAMA Psychiatry. 2015;72(8):745–6.

    Article  PubMed  Google Scholar 

  26. Iyer S, Banks N, Roy M-A, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I—patient perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):14S–22S.

    PubMed  Google Scholar 

  27. Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684–90.

    Article  PubMed  Google Scholar 

  28. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with ethical standards

The article was adapted from CNS Drugs 2016;30(8):689–701 [1] by salaried employees of Adis/Springer and was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies. Drugs Ther Perspect 33, 28–31 (2017). https://doi.org/10.1007/s40267-016-0345-y

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0345-y

    Search

    Navigation